Androstenes

"Androstenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.

Descriptor ID	D000736
MeSH Number(s)	D04.210.500.054.079
Concept/Terms	Androstenes Androstenes

Below are MeSH descriptors whose meaning is more general than "Androstenes".

Chemicals and Drugs [D]
Polycyclic Compounds [D04]
Fused-Ring Compounds [D04.210]
Steroids [D04.210.500]
Androstanes [D04.210.500.054]
Androstenes [D04.210.500.054.079]

Below are MeSH descriptors whose meaning is related to "Androstenes".

Below are MeSH descriptors whose meaning is more specific than "Androstenes".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Androstenes" by people in this website by year, and whether "Androstenes" was a major or minor topic of these publications.

Bar chart showing 25 publications over 13 distinct years, with a maximum of 4 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	0	1	1
2011	0	1	1
2014	1	2	3
2015	1	1	2
2016	0	1	1
2017	0	3	3
2018	0	1	1
2019	1	1	2
2020	0	2	2
2021	0	2	2
2022	0	2	2
2023	1	0	1
2024	3	1	4

Below are the most recent publications written about "Androstenes" by people in Profiles.

La Cerda J, Thorley J, Sieber P, Cookson MS, Flanders SC, Gatoulis SC, Shore ND. Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. Future Oncol. 2025 Jan; 21(1):51-62.

View in: PubMed
Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schl?rmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. 2025 Apr; 8(2):394-406.

View in: PubMed
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fl?chon A, Wei XX, Mahammedi H, Roubaud G, ?tudentov? H, Nagarajah J, Mellado B, Montesa-Pino ?, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024 09 28; 404(10459):1227-1239.

View in: PubMed
Nikita N, Gandhi K, Keith SW, Sharma S, Kelly WK, Lu-Yao G. The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study. J Geriatr Oncol. 2024 06; 15(5):101773.

View in: PubMed
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schl?rmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 10; 24(10):1094-1108.

View in: PubMed
Shah YB, Shaver AL, Kelly WK, Lu-Yao G. A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. PLoS One. 2022; 17(8):e0273826.

View in: PubMed
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schl?rmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022 Sep; 1(9):EVIDoa2200043.

View in: PubMed
Shore ND, Ionescu-Ittu R, Lalibert? F, Yang L, Lejeune D, Yu L, Duh MS, Mahendran M, Kim J, Ghate SR. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Clin Genitourin Cancer. 2021 12; 19(6):480-490.

View in: PubMed
Saad F, Chi KN, Shore ND, Graff JN, Posadas EM, Lattouf JB, Espina BM, Zhu E, Yu A, Hazra A, De Meulder M, Mamidi RNVS, Bradic B, Francis P, Hayreh V, Rezazadeh Kalebasty A. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemother Pharmacol. 2021 07; 88(1):25-37.

View in: PubMed
Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor O. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 12; 23(4):680-688.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement